Related Experiment Video
Updated: Oct 9, 2025
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
1.8K
Epigenetic modification and BRAF gene mutation in thyroid carcinoma.
Guo Huang1,2, Juan Chen3, Jun Zhou1,2
1Hengyang Medical College, University of South China, Hengyang, 421001, Hunan, China.
Cancer Cell International
|December 20, 2021
Summary
Thyroid cancer, primarily differentiated thyroid carcinomas, shows increasing incidence. This review highlights the crucial roles of epigenetic modifications and BRAF mutations in thyroid cancer development and treatment strategies.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Thyroid cancer is the most common endocrine malignancy, with differentiated thyroid carcinomas accounting for 95% of cases.
- The incidence of thyroid cancer is increasing, necessitating further research into its underlying mechanisms.
- Gene mutations and epigenetic changes are recognized as key factors in thyroid cancer development.
Purpose of the Study:
- To review the significance of epigenetic modifications in thyroid cancer.
- To discuss the role of BRAF gene mutations in thyroid cancer pathogenesis.
- To explore the implications of these factors in thyroid cancer treatment.
Main Methods:
- Literature review focusing on epigenetic modifications (DNA methylation, chromatin remodeling, noncoding RNA, histone modification) and BRAF mutations in thyroid cancer.
- Analysis of current understanding of molecular mechanisms in thyroid cancer development.
- Synthesis of information regarding therapeutic strategies targeting epigenetic alterations and BRAF mutations.
Main Results:
- Epigenetic modifications, including DNA methylation and histone alterations, significantly influence gene expression in thyroid cancer.
- BRAF mutations are frequently observed in differentiated thyroid carcinomas and are implicated in tumor progression.
- Understanding these molecular drivers is crucial for developing targeted therapies.
Conclusions:
- Epigenetic dysregulation and BRAF mutations are pivotal in the pathogenesis of thyroid cancer.
- Targeting epigenetic modifications and BRAF mutations holds promise for improved thyroid cancer treatment outcomes.
- Further research is needed to fully elucidate the complex molecular landscape of thyroid cancer.
Related Concept Videos
02:38The Ras Gene
6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.5K
01:20The Retinoblastoma Gene
4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
01:25Mutagenicity and Carcinogenicity
1.5K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.5K
01:20Synthesis and Regulation of Thyroid Hormones
5.5K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.5K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:23Abnormal Proliferation
4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K